JAK3 and mature T-cell and NK-cell non-Hodgkin lymphoma: In light of the finding of activating mutations in JAK3 in multiple subtypes of PTCL, including our study, it will be important to investigate the use of these inhibitors for the treatment of these malignancies [42, 59].